Loading...
Zydus Lifesciences' Desidustat Drug Gains NMPA Approval in China
LIVE TV
LOCAL
Tour
ENGLISH
For You
Entertainment
National
Sports
Markets
Business & Economy
Lifestyle
World
Astrology & Religion
Technology
Education & Jobs
Auto
Politics
Viral
Opinions
Loading more articles...
Home
Local
Live TV
Zydus Lifesciences' Desidustat gets China NMPA approval for renal anaemia
N
News18
•
14-03-2026, 19:15
Zydus Lifesciences' Desidustat gets China NMPA approval for renal anaemia
•
Zydus Lifesciences' innovative drug Desidustat tablets received approval from China's National Medical Products Administration (NMPA).
•
The drug is approved for treating renal anaemia in patients suffering from Chronic Kidney Disease (CKD).
•
Zydus licensed Desidustat to CMS International Development and Management Ltd, a subsidiary of China Medical System Holdings Ltd, in 2020.
•
Zydus MD Sharvil P Patel highlighted the commitment to improving patient outcomes globally and expanding access in Greater China.
•
Marketed as Oxemia in India, Desidustat has treated over 100,000 CKD patients since 2022; China has over 120 million CKD patients with unmet needs.
Read Full Article on News18 in English
✦
More like this
✦
More like this
China Cracks Down on Traditional Medicine Injections, One-Third Face Removal
F
Firstpost
Mahalaxmi Rajyog 2026: 3 Zodiacs to experience wealth, success, and joy!
N
News18
Ghaziabad Alarmed: Vitamin D, B12 Deficiencies Soar, Women & Youth Most Affected
N
News18
China Warns Against 'Regime Change' Amid Iran Tensions, Urges Diplomacy
C
CNBC Awaaz
Mahalaxmi Rajyog 2026: March 16 brings fortune for Taurus, Cancer, Scorpio!
N
News18
Abbott, Novo Nordisk Partner to Launch New Diabetes Medication in India
N
News18